Rutgers University 4R Symposium: Radiotherapy and Immunotherapy: At the Crossroads

Rutgers University 4R Symposium: Radiotherapy and Immunotherapy: At the Crossroads Banner

Add to Calendar Rutgers University 4R Symposium: Radiotherapy and Immunotherapy: At the Crossroads 10/10/2019 8:00:00 AM 10/10/2019 5:00:00 PM America/New_York Rutgers CINJ, 195 Little Albany Street, 1st Floor Aud. A false MM/DD/YYYY


Date & Location
Thursday, October 10, 2019, 8:00 AM - 5:00 PM, Rutgers CINJ, 195 Little Albany Street, 1st Floor Aud. A, New Brunswick, NJ

Overview

Pre-registration is now closed. On site registration will be available.


Immunotherapy has made significant progress in recent years, not only in lab research but also, more importantly, in clinical treatment and management of cancer patients. It has been proven to be very effective in curing several types of cancer and in improving treatment efficacy on others.

This symposium will provide participants with an overview of new advances in the use of radiotherapy in combination with immunotherapy. New research developments in this area will be presented to advance the integration of these findings into individualized radiation therapy clinical applications with the goal of improved patient outcomes. It is critical that participants are aware of these advances and implement them into clinical practice. Participants should be able to acquire high-quality genomic information with consistency in all diagnostic efforts. Therefore, continually understanding the emerging technologies of acquiring genetic information is essential.

Symposium Director's Message
Dear Radiation Oncology, Radiation Biology and Medical Physics Colleagues:

On behalf of the Radiation Oncology Department of Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School and New Jersey Medical School, we welcome you to the 3rd bi-annual Rutgers Radiation Oncology 4R Symposium: Radiotherapy and Immunotherapy: At the Crossroads.

The symposium will be a one-day gathering of thought leaders who are pushing the frontiers of radiation oncology by integrating precision medicine into research and treatment. The overall goal of the meeting will be to explore the development of personalized radiation therapy using new advances in genomic- and biology-based biomarkers, in addition to existing clinical and pathologic features, in combination with select drugs targeted to improve patient outcomes. We have secured an outstanding group of speakers who will give talks in three tracks: Biology, Clinical/Translational and Physics.

We are fortunate in being able to offer this outstanding program without any fees and we will provide up to 5.0 CME/CEU credits for participation in the conference.

Attendance at the last 4R Symposium in 2017 exceeded expectations and was at capacity. Therefore, we ask that you pre-register as soon as possible to secure a seat at the 2019 Symposium.

We look forward to seeing you.

Sincerely




Symposium Directors

Bruce G. Haffty, MD, Associate Vice Chancellor Cancer Programs, Rutgers Biomedical and Health Sciences; Chief of Staff, Rutgers Cancer Institute of New Jersey; Professor and Chair, Department of Radiation Oncology, Rutgers Robert Wood Johnson, Rutgers New Jersey Medical School, and Rutgers Cancer Institute of New Jersey

Salma K. Jabbour, MD, Professor and Vice Chair of Clinical Research and Faculty Development, Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School

Zhiyuan Shen, MD, PhD, Professor and Chief, Division of Radiation Cancer Biology, Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School

Ning Jeff Yue, PhD, Professor, Executive Vice Chair and Chief, Division of Medical Physics, Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School

Program Committee

Edouard L. Azzam, PhD, MSc, Professor of Radiology, New Jersey Medical School

Zhaohui Feng, MD, PhD, Associate Professor of Radiation Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School

Michael L. Gatza, PhD, Assistant Professor of Radiation Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School

Wenwei Hu, PhD, Professor of Radiation Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School

Ke Nie, PhD, Associate Professor, Program Director, Medical Physics Residency Program, and Director of GammaKnife Physics, Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School

Rahul R. Parikh, MD, Associate Professor of Radiation Oncology; Medical Director, Laurie Proton Beam Center, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School

Bing Xia, PhD, Professor of Radiation Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School

Dallas Sanchez, Administrative Analyst II, Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School

Sharda Kohli, MBA, Senior Director of Administration, Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School

Target Audience
This activity is designed for radiation oncology clinicians, radiobiologists, medical physicists, researchers, residents, fellows, medical students and other allied health professionals involved in radiotherapy treatment and research.

Objectives

Upon completion of this activity, participants should be better able to:
  1. Examine the current and future directions of physics research in radiation oncology and the clinical implementations of new technologies in combination with immunotherapy
  2. Describe recent discoveries of cancer biology research involving the mechanisms of biological response of cancer and normal cells to radiation combined with immunotherapy
  3. Review recent advances in radiation oncology clinical/translational research and their applications in combination with immunotherapy to improved patient care

Registration
Registration Fee - Complimentary

Registration is required and can only be accepted through our secure on-line website until October 7, 2019. Continental breakfast, refreshment breaks, lunch, continuing education credit, and course material will be provided free of charge.

Pre-registration is strongly recommended. On-site registration will be accommodated on a space available basis.

Confirmation
Once registered, you will receive a confirmation message and additional information to assist you with your plans to participate in this activity.

Cancellation
We anticipate the meeting room to be near or at seating capacity. If you are unable to attend, we would greatly appreciate it if you could cancel your registration so that we may able to accommodate others who have an interest in attending. To cancel, email your cancellation request to ccoe@rbhs.rutgers.edu.

Questions
Registration: Contact CCOE by email at ccoe@rbhs.rutgers.edu
Course Information: Contact Sharda Kohli, MBA by email at kohlish@cinj.rutgers.edu or by phone at 732-235-6144

Rutgers reserves the right to modify program content, faculty and program activities. It also reserves the right to cancel the activity if necessary. Rutgers is not responsible for any costs purchased for attendance at this activity if the activity is cancelled.

Accreditation and Credit Designation

In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians: Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medical Physicists: Rutgers Cancer Institute of New Jersey has applied to CAMPEP for approval of 5 MPCEC hours for this activity.

Advanced Practice Nurses, Nurses and Physician Assistants may participate in this educational activity and earn a letter of attendance as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.

Method of Participation
In order to meet the learning objectives and receive continuing education credits, participants are expected to check in at the registration desk, attend the program and complete an online evaluation form at the conclusion of the activity. A letter certifying attendance and credit verification will be emailed to participants upon completion of the online evaluation survey.

Course Material
In an effort to provide the most complete materials to attendees and conserve resources, PDF versions of the lecture slides will be made available online to registered attendees. In addition, internet access will be available during the day of the activity so we encourage attendees to bring a laptop or tablet. Additional information will be provided in future confirmation communication.